Contravisory Investment Management’s Charles River Laboratories CRL Stock Holding History

Contravisory Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,218	Closed	-$1.07M	–	405
2026 Q1	$1.07M	Buy	6,218 +89	+1%	+$16.5K	0.22%	73
2025 Q4	$1.22M	Buy	+6,129	New	+$1.11M	0.24%	53
2024 Q3	–	Sell	-2,868	Closed	-$592K	–	361
2024 Q2	$592K	Buy	+2,868	New	+$650K	0.13%	99
2018 Q1	–	Sell	-13	Closed	-$1K	–	354
2017 Q4	$1K	Hold	13	–	–	﹤0.01%	353
2017 Q3	$1K	Buy	+13	New	+$1.34K	﹤0.01%	399

Other funds holding CRL

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

IHL

Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return

CPCPP

Canada Post Corporation Pension Plan Toronto, Canada $2.87B AUM 37.96% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

CCMINC

Cardinal Capital Management Inc (North Carolina) Raleigh, North Carolina $826M AUM 32.06% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Contravisory Investment Management's CRL Position: Q2 2026 in Review

Contravisory Investment Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 6,218 shares — an estimated $1.07M sold.

Contravisory Investment Management first reported a position in CRL in Q3 2017 and held it in 5 quarters. The position peaked at $1.22M in Q4 2025. 82 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Contravisory Investment Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
Contravisory Investment Management sold 6,218 Charles River Laboratories shares in Q2 2026, an estimated $1.07M.
Contravisory Investment Management first reported a position in Charles River Laboratories in Q3 2017 and held it in 5 quarters.
Contravisory Investment Management's Charles River Laboratories position peaked at $1.22M in Q4 2025.
82 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.